Prosecution Insights
Last updated: April 19, 2026
Application No. 18/033,964

MATRIX METALLOPROTEASE 1 EXPRESSION INHIBITOR, SKIN EXTERNAL AGENT, AND USE FOR INHIBITION OF MATRIX METALLOPROTEASE 1 EXPRESSION

Non-Final OA §102§112
Filed
Nov 03, 2023
Examiner
CHEN, CATHERYNE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dsr Corporation
OA Round
1 (Non-Final)
37%
Grant Probability
At Risk
1-2
OA Rounds
4y 7m
To Grant
55%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allow Rate
284 granted / 769 resolved
-23.1% vs TC avg
Strong +18% interview lift
Without
With
+18.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 7m
Avg Prosecution
48 currently pending
Career history
817
Total Applications
across all art units

Statute-Specific Performance

§101
13.5%
-26.5% vs TC avg
§103
40.2%
+0.2% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 769 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 11-13 are pending. Claims 11-13 are examined on the merits. Election/Restrictions Applicant’s election of the species an extract of hops in the reply filed on 11/24/2025 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Information Disclosure Statement The information disclosure statements (IDSs) submitted on 12/8/2025, 7/25/2025, 5/12/2023, 4/26/2023 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. The signed IDS forms are attached with the instant office action. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims12-13 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In Claim 12, the term “mass” is indefinite. It is not clear what amounts of the substance need to be present in order for the compositions to be considered “by mass” in these compounds. “Mass” is an inherent part of the chemical matter that cannot be changed. Is Applicant claiming weight? Please amend or explain. In Claim 13, the term “base” is indefinite because one does not know what is meant by “base” as “base” has many terms and meanings. Is Applicant claiming the protein kinase C-delta inhibitor attached to something or is it dissolved in a carrier substrate? Please clarify or amend. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 11-13 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Li et al. (CN 111135133 A). Li et al. teaches a method of using cosmetic preparation using beer brewing residue extract comprising 1% hops extract in deionized water (page 6, Example 6). Water can be a base for cosmetics. The cosmetics is applied to skin (Table 4). The same hops extract would have the same effect at the same concentration and same application to skin. Therefore, the reference anticipates the claims. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERYNE CHEN whose telephone number is (571)272-9947. The examiner can normally be reached on Monday-Friday 9-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice . If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Catheryne Chen Examiner Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Nov 03, 2023
Application Filed
Apr 26, 2023
Response after Non-Final Action
Oct 02, 2025
Examiner Interview Summary
Oct 02, 2025
Applicant Interview (Telephonic)
Jan 07, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589184
CLINICAL DRESSING LOADED WITH COFFEE EXTRACT
2y 5m to grant Granted Mar 31, 2026
Patent 12569424
STABLE VITAMIN C COMPOSITIONS
2y 5m to grant Granted Mar 10, 2026
Patent 12551521
COMPOSITIONS INCLUDING PINE BARK EXTRACT, BERRYFRUIT EXTRACT AND A SOURCE OF L-THEANINE AND USES THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12551520
MAQUI BERRY EXTRACTS FOR TREATMENT OF SKIN DISEASES
2y 5m to grant Granted Feb 17, 2026
Patent 12544352
DIAPER CREAM
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
37%
Grant Probability
55%
With Interview (+18.4%)
4y 7m
Median Time to Grant
Low
PTA Risk
Based on 769 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month